Search results
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 5 days agoSource: Global Cancer Observatory. Analysts forecast Novartis' second-quarter earnings per share to be between $1.78 and $1.84...
Lurie takes charge in studying drug that glows in presence of lung cancer cells
Crain s Chicago Business· 5 days agoFood & Drug Administration for Investigational New Drug approval to study the safety and feasibility ...
7 Benefits of Metformin (Including Weight Loss)
MediaFeed via AOL· 3 days agoMetformin is the most commonly prescribed oral drug for diabetes. Of course, if you or a loved one receives treatment for diabetes, you probably already...
GT Medical and Theragenics team up to expand access to radiotherapy seeds
Medical Device Network via Yahoo Finance· 4 days agoCesium-131 is a common isotope used with low dose rate (LDR) brachytherapy, a radiation treatment...
You Can Test Your Blood for 50 Kinds of Cancer
The Atlantic· 4 days agoIt takes a certain amount of confidence to call your biotech company Grail. According to its website, the Menlo Park–based firm got its name because its “co-founders believed a simple blood ...
Tips For Seniors Over 65 With ED
MediaFeed via AOL· 6 days agoCan an 80-year-old man get hard? The short answer is yes. But there are some reasons why it may be more difficult for older men to get aroused during...
Xyosted: Mild to serious side effects and how to manage them
Medical News Today· 4 days agoXyosted (testosterone enanthate) is a brand-name injectable drug that’s prescribed for testosterone...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
FOX 4 Kansas City· 3 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
WTNH-TV New Haven· 3 days agoJohnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study...
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Morningstar· 7 days agoMore than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment optionsThe first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable ...